Form 4: Incyte Corp Executive Matteo Trotta Reports Stock Transaction
SEC Form 4 Filing
EVP and GM of Dermatology US, Matteo Trotta, reports disposition of Incyte Corp common stock to cover tax obligations.
Summary
- On March 25, 2025, Matteo Trotta, EVP and GM of Dermatology US at Incyte Corp, disposed of 537 shares of common stock to cover tax withholding obligations.
- The transaction was executed at a price of $62.08 per share.
- Following the transaction, Trotta directly owns 9,937 shares of Incyte Corp common stock, which includes 8,517 unvested shares of common stock issuable pursuant to previously reported restricted stock units.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing reflects a routine transaction for tax purposes and doesn't indicate a significant change in the executive's holdings or confidence in the company.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track executive sentiment and potential alignment with shareholder interests.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a small sale of shares by an executive for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 03/25/2025 | Date of stock transaction (disposal of shares). |
| 03/27/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Incyte Corp, Matteo Trotta, Stock Transaction, Beneficial Ownership, Executive Compensation, Dermatology, INCY
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.